Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2022
Reporting Period: This filing announces financial results for the year and quarter ended December 31, 2021. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in this document.
- Profit/Loss: Not provided in this document.
- Cash Flow: Not provided in this document.
- Margins: Not provided in this document.
- Debt and Liquidity: Not provided in this document.
Material Changes
The filing text does not provide specific data to compare against prior periods. It serves only to notify investors that results for the period ended December 31, 2021, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Company issued a press release on March 8, 2022, announcing its financial results. The full text of this commentary is incorporated by reference in Exhibit 99.1.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 8, 2022) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" which are referenced but not detailed in this 8-K cover sheet.
- Confirm the trading symbol (MTNB) and exchange (NYSE American) for accurate market data lookup.